EML4 and non-small cell lung carcinoma: Additionally, we detected the SQSTM1‐ALK fusion exclusively in the EBC sample, highlighting a relatively rare but clinically significant variant in NSCLC, seen in approximately 1.1% of cases, in contrast to the more common EML4‐ALK fusions, which represent about 81.5% of all ALK fusions.